(firstQuint)FG-4592 for Treatment of Anemia in Subjects With Chronic Kidney Disease Not on Dialysis.

 This is a randomized, multicenter, double-blind, placebo-controlled study of the treatment of anemia in subjects with CKD not on dialysis.

 Eligible subjects are randomized to FG-4592 or placebo at a ratio of 2:1.

 The primary endpoint is change in Hb from baseline to the average level during Weeks 7 to 9 inclusive.

.

 FG-4592 for Treatment of Anemia in Subjects With Chronic Kidney Disease Not on Dialysis@highlight

This is a randomized, multicenter, double-blind, placebo-controlled study of the treatment of anemia in subjects with CKD not on dialysis, with treatment up to 52 weeks.

